PharmTech Drug Digest 11.20
News|Articles|July 6, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-08-02-2017
  • Volume 12
  • Issue 8

PCI Pharma Services Expands Serialization Capability at Wales Site

The suite installation increases PCI’s Hay-on-Wye site’s serialization capability to support clients in advance of meeting the implementation dates of the European Falsified Medicines Directive.

Outsourcing services provider PCI Pharma Services (PCI) announced a significant expansion of its serialization capability at its Hay-on-Wye site, Wales, United Kingdom. The suite installation increases the site’s capacity to support clients preparing for the serialization deadline of the European Falsified Medicines Directive (EU FMD). 

The flexible technology delivers machine and human-readable coding, tamper-evident solutions and Bollini labelling-which in turn is linked to a case loading and aggregation station, with a final aggregation station compacting cases to pallet. PCI supports the advanced use of aggregation to realize the significant benefits in packaging operations, as well as the broader pharmaceutical supply chain.

PCI’s serialization solution has been designed for flexibility and ease of use for a variety of client package styles and applications. The suite includes strategically located multi-position laser and thermal inkjet coding heads, with associated inspection cameras to deliver ultimate flexibility in configuration, location, and type of coding. This includes multi-position tamper-evident labelling heads to support a full-service solution to satisfy the requirements of the EU FMD. The system is able to effectively manage a broad range of sizes and package styles, with significant high-speed application. 

This investment in PCI’s Hay facility is the first phase of a multi-stage installation of expanded serialization capacity at the site. In February 2017, PCI announced an investment that will triple its serialization capacity across its global network in preparation for the pending DCSCA deadline.

PCI has been serializing commercial products for the US, European, and international markets for the past five years. The company-wide software strategy enables operators in all PCI’s global locations to operate the same graphical user interface, providing a seamless global service.

PCI has partnered with Antares Vision, Crest Solutions, and Xyntek for this latest installation, utilizing Antares’ leading serialization platform and technology architecture. This installation supports a variety of drug-delivery forms, including bottles, unit cartons, and parenteral kits, as well as unit dose wallets and child-resistant/compliance prompting packaging. 

Source: PCI

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.